Fever with rash following zolendronic acid administration.
Rizos
E C
EC
Milionis
H J
HJ
Elisaf
M S
MS
D000284:Administration, Oral; D000982:Antipruritics / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005076:Exanthema / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D005334:Fever / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D007275:Injections, Intravenous; D017336:Loratadine / Q000627:therapeutic use; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D000982:Antipruritics; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D007093:Imidazoles; D000077211:Zoledronic Acid; D017336:Loratadine; D011241:Prednisone